亞邦絲醫療 INVA 深 滬
等待開盤 04-02 09:30:00 美东时间
23.41
+0.110
+0.47%
華盛通- 最 高23.63
- 今 開23.54
- 成交量 61.79万股
- 最 低 23.105
- 昨 收 23.30
- 總市值 17.34亿
- 52周最高 25.145
- 市盈率 靜 7.09
- 換手率 0.83%
- 52周最低 16.52
- 委 比 30.33%
- 總股本 7405.14万
- 歷史最高 41.96
- 量 比 0.68
- 振 幅 2.25%
- 歷史最低 6.36
- 每 手 1
- 風險率 1.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
BTIG Reiterates Buy on Innoviva, Maintains $35 Price Target
BTIG analyst Julian Harrison reiterates Innoviva (NASDAQ:INVA) with a Buy and maintains $35 price target.
02-26 20:54
Innoviva Q4 EPS $1.94 Beats $0.66 Estimate, Sales $114.613M Beat $101.530M Estimate
Innoviva (NASDAQ:INVA) reported quarterly earnings of $1.94 per share which beat the analyst consensus estimate of $0.66 by 195.28 percent. This is a 646.15 percent increase over earnings of $0.26 per share from the same
02-26 07:38
美股大行评级 | 潜在涨幅1226.53%！RenovoRx获Ascendiant Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从12.5美元升至13美元；Lake Street：维持Insight Molecular"买入"评级，目标价从8美元升至12美元
02-18 16:48
BTIG Initiates Coverage On Innoviva with Buy Rating, Announces Price Target of $35
BTIG analyst Julian Harrison initiates coverage on Innoviva (NASDAQ:INVA) with a Buy rating and announces Price Target of $35.
02-17 19:33
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
Cantor Fitzgerald Maintains Overweight on Innoviva, Raises Price Target to $31
Cantor Fitzgerald analyst Steve Seedhouse maintains Innoviva (NASDAQ:INVA) with a Overweight and raises the price target from $29 to $31.
2025-11-06 22:42
Innoviva Q3 EPS $1.08 Beats $0.52 Estimate, Sales $107.800M Beat $91.309M Estimate
Innoviva (NASDAQ:INVA) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $0.52 by 109.71 percent. This is a 5300 percent increase over earnings of $0.02 per share from the same
2025-11-06 05:47
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
2025-10-01 20:13
